Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Bnz-1, a Selective γ-Chain Cytokine Inhibitor Has Clinical Activity in Patients with Cutaneous T Cell Lymphoma By Selectively Blocking IL-2, IL-15 and IL-9 Signaling: Results of a Multicenter, Open-Label Phase 1 Trial

Christiane Querfeld, MD PhD, Basem M. William, MRCP,MD, Jonathan E. Brammer, MD, Lubomir Sokol, MD PhD, Yutaka Tagaya, MD PhD, Paul Frohna, MD PhD PharmD, Nazli Azimi, PhD PharmD, Jasmine M. Zain, MD

Blood (2019) 134 (Supplement_1): 1557.

https://doi.org/10.1182/blood-2019-129201

Published: 2019

Journal Articles

Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression and Gene Expression Profile

Christiane Querfeld, MD PhD, Xiwei Wu, PhD, Tracy Stiller, MS, Joycelynne Palmer, PhD, James F Sanchez, PhD, Xochiquetzal Martinez, MD, Steven Rosen, MD, Jasmine Zain, MD

Blood (2019) 134 (Supplement_1): 4024.

https://doi.org/10.1182/blood-2019-126358

Published: 2019

Journal Articles

Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study

Youn H. Kim, MD, Martine Bagot, MD PhD, Pier Luigi Zinzani, MD PhD, Madeleine Duvic, MD, Stephen Morris, MBBS, MRCP, FRCR, Ellen Kim, MD, Amy Musiek, MD, Pablo L. Ortiz-Romero, MD PhD, Craig Elmets, MD, Herbert A. Eradat, MDMS, Nina Magnolo, MD, Julia Scarisbrick, MD, Stéphane Dalle, MD PhD, David C. Fisher, MD PhD, Michi Shinohara, MD, Brian Poligone, MD PhD, Barbara Pro, MD, Pietro Quaglino, MD, Nishitha Reddy, MD MSCI, Brigitte Dreno, MD, Larisa J Geskin, MD, Ahmad S Halwani, MD, Amit Khot, MD, Marie Beylot-Barry, MD PhD, Neil Korman, MD, Frederick Lansigan, MD, Steven M. Horwitz, MD, Zanetta S. Lamar, MD, Alison J. Moskowitz, MD, Jillian Wells, MD, Oleg E. Akilov, MD PhD, Dolores Caballero, MD PhD, Richard Cowan, MBBS, MD MRCP, FRCR, Reinhard Dummer, MD, Mary Jo Lechowicz, MD, Francine M. Foss, MD, Lars Iversen, MD, Tomomitsu Miyagaki, MD PhD, Ryan Wilcox, MD, Pierluigi Porcu, MD, Maarten Vermeer, MD PhD, Sunil Abhyankar, MD, Yukihiko Kato, MD PhD, Theresa Pacheco, MD, Shigetoshi Sano, MD PhD, Basem M. William, MRCP,MD, Timothy S. Fenske, MD, Noriko Fukuhara, MD PhD, Koji Habe, MD PhD, Toshihisa Hamada, MD PhD, Eiji Kiyohara, MD PhD, Bryone J. Kuss, MBBS, PhD FRACP, FRCPA, Adam Lerner, MD, Lawrence Mark, MD PhD, Javier Munoz, MD, Hiroyuki Okamoto, MD PhD, Christiane Querfeld, MD PhD, Jiro Uehara, MD, Hisashi Uhara, MD PhD, Kentaro Yonekura, MD PhD, Auris Huen, MD, Kensei Tobinai, MD PhD, Yoshiki Tokura, MD PhD, Erin Boh, MD PhD, Jan Nicolay, MD, Hidefumi Wada, MD, Mollie Leoni, MD, Takahiro Ito, MSc, Fiona Herr, PhD, Lubomir Sokol, MD PhD

Blood (2019) 134 (Supplement_1): 5300.

https://doi.org/10.1182/blood-2019-122778

Published: 2019

Journal Articles

PD-L1 Expression Is Regulated By microRNAs-21 and -130 in Cutaneous T-Cell Lymphoma

Renee Estephan, BS, Sung Hee Kil, PhD, Steven T Rosen, Christiane Querfeld, MD PhD

Blood (2018) 132 (Supplement 1): 4108.

https://doi.org/10.1182/blood-2018-99-115064

Published: 2018

Journal Articles

Phase 1/2 Trial of Durvalumab and Lenalidomide in Patients with Cutaneous T Cell Lymphoma (CTCL): Preliminary Results of Phase I Results and Correlative Studies

Christiane Querfeld, MD PhD, Jasmine M. Zain, MD, Devin L. Wakefield, PhD, Tijana Jovanovic-Talisman, PhD, Sung Hee Kil, PhD, Renee Estephan, BS, James Sanchez, PhD, Joycelynne Palmer, Steven T Rosen

Blood (2018) 132 (Supplement 1): 2931.

https://doi.org/10.1182/blood-2018-99-114001

Published: 2018

Journal Articles

Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase I Trial

Christiane Querfeld, MD PhD, John Thompson, MD, Matthew H. Taylor, MD, Raju Pillai, MD, Lisa DS Johnson, PhD, Tina Catalano, MSc, Penka S. Petrova, PhD, Theresa Thompson, Robert A. Uger, PhD, Yaping Shou, MD PhD, Oleg E. Akilov, MD

Blood (2018) 132 (Supplement 1): 1653.

https://doi.org/10.1182/blood-2018-99-116915

Published: 2018

Journal Articles

Phase 1 Trial of Cobomarsen, an Inhibitor of Mir-155, in Cutaneous T Cell Lymphoma

Blood (2018) 132 (Supplement 1): 2903.

https://doi.org/10.1182/blood-2018-99-119861

Published: 2018

Journal Articles

Dissecting the Roles of p38β and p38γ in Cutaneous T Cell Lymphoma

Xu Hannah Zhang, PhD, Christiane Querfeld, MD PhD, Steven T Rosen

Blood (2018) 132 (Supplement 1): 2866.

https://doi.org/10.1182/blood-2018-99-118992

Published: 2018

Journal Articles

A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 "Do Not Eat" Signal

Christiane Querfeld, MD PhD, John Thompson, MD, Matthew Taylor, Raju Pillai, MD, Lisa DS Johnson, PhD, Tina Catalano, MSc, Penka S. Petrova, PhD, Robert A. Uger, PhD, Meghan Irwin, BSc, EMBA, Eric L Sievers, MD, Oleg E. Akilov, MD

Blood (2017) 130 (Supplement 1): 4076.

https://doi.org/10.1182/blood.V130.Suppl_1.4076.4076

Published: 2017

Journal Articles

Phase 1 Study of the Safety and Efficacy of MRG-106, a Synthetic Inhibitor of microRNA-155, in CTCL Patients

Blood (2017) 130 (Supplement 1): 820.

https://doi.org/10.1182/blood.V130.Suppl_1.820.820

Published: 2017

Journal Articles

PD-L1 Is Regulated By Interferon Gamma and Interleukin 6 through STAT1 and STAT3 Signaling in Cutaneous T-Cell Lymphoma

Sung Hee Kil, PhD, Renee Estephan, BS, James Sanchez, PhD, Jasmine M. Zain, MD, Marshall E. Kadin, MD, James W. Young, MD, Steven T. Rosen, MD, Christiane Querfeld, MD PhD

Blood (2017) 130 (Supplement 1): 1458.

https://doi.org/10.1182/blood.V130.Suppl_1.1458.1458

Published: 2017

Journal Articles

Preliminary Results of a Phase 1 Trial Evaluating MRG-106, a Synthetic microRNA Antagonist (LNA antimiR) of microRNA-155, in Patients with CTCL

Christiane Querfeld, MD PhD, Theresa Pacheco, MD, Francine M. Foss, MD, Ahmad S. Halwani, MD, Pierluigi Porcu, MD, Anita G Seto, PhD, Judy Ruckman, PhD, Michele L Landry, Aimee L Jackson, PhD, Linda A Pestano, PhD, Brent A Dickinson, Mark Sanseverino, David M Rodman, MD, Gilad Gordon, MD MBA, William Marshall, PhD

Blood (2016) 128 (22): 1829.

https://doi.org/10.1182/blood.V128.22.1829.1829

Published: 2016

Journal Articles

Role of p38γ - NFATc4 - IL17A Pathway As a Potential Therapeutic Target in Cutaneous T Cell Lymphoma

Xu Hannah Zhang, PhD, Vu N. Ngo, PhD, Natalie Sandoval, MSc, Qi Cui, Yanhong Shi, PhD, Jasmine M. Zain, MD, Christiane Querfeld, MD PhD, Chao Guo, Xiwei Wu, PhD, Steven T. Rosen, MD

Blood (2016) 128 (22): 2725.

https://doi.org/10.1182/blood.V128.22.2725.2725

Published: 2016

Journal Articles

The miRNA Profile of Cutaneous T Cell Lymphoma Correlates with the Dysfunctional Immunophenotype of the Disease

Christiane Querfeld, MD PhD, Xiwei Wu, PhD, James F Sanchez, PhD, Joycelynne M. Palmer, PhD, Azadeh Motevalli, PhD, Jasmine Zain, MD, Steven T. Rosen, MD

Blood (2016) 128 (22): 4132.

https://doi.org/10.1182/blood.V128.22.4132.4132

Published: 2016

Journal Articles

Clinicopathologic Features, Prognosis, and Therapeutic Responses in Patients with Granulomatous Mycosis Fungoides: A Single Center Experience From Memorial Sloan Kettering Cancer Center.

Janet Y. Li, BA, Melissa Pulitzer, MD, Patricia L. Myskowski, MD, Steven Dusza, Dr.PH, Steven M. Horwitz, MD, Alison Moskowitz, MD, Christiane Querfeld, MD, PhD

Blood (2012) 120 (21): 2643.

https://doi.org/10.1182/blood.V120.21.2643.2643

Published: 2012

Journal Articles

Pralatrexate in Relapsed/Refractory HTLV-1 Associated Adult T-Cell Lymphoma/Leukemia: A New York City Multi-Institutional Experience.

Matthew A Lunning, DO, Jason Gonsky, MD, PhD, Jia Ruan, MD, PhD, Adrienne A. Phillips, MD, MPH, Melissa Pulitzer, MD, Alison Moskowitz, MD, Christiane Querfeld, MD PhD, Patricia L Myskowski, M.D., Ariela Noy, MD, Steven M. Horwitz, MD

Blood (2012) 120 (21): 2735.

https://doi.org/10.1182/blood.V120.21.2735.2735

Published: 2012

Journal Articles

Phase II Multicenter Trial of Lenalidomide: Clinical and Immunomodulatory Effects in Patients with CTCL

Christiane Querfeld, MD, PhD, Steven T. Rosen, MD, Joan Guitart, MD, Madeleine Duvic, MD, Youn H. Kim, MD, Charles Goolsby, PhD, Timothy Kuzel, MD

Blood (2011) 118 (21): 1638.

https://doi.org/10.1182/blood.V118.21.1638.1638

Published: 2011

NARROW

Bnz-1, a Selective γ-Chain Cytokine Inhibitor Has Clinical Activity in Patients with Cutaneous T Cell Lymphoma By Selectively Blocking IL-2, IL-15 and IL-9 Signaling: Results of a Multicenter, Open-Label Phase 1 Trial

Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression and Gene Expression Profile

Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study

PD-L1 Expression Is Regulated By microRNAs-21 and -130 in Cutaneous T-Cell Lymphoma

Phase 1/2 Trial of Durvalumab and Lenalidomide in Patients with Cutaneous T Cell Lymphoma (CTCL): Preliminary Results of Phase I Results and Correlative Studies

Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase I Trial

Phase 1 Trial of Cobomarsen, an Inhibitor of Mir-155, in Cutaneous T Cell Lymphoma

Dissecting the Roles of p38β and p38γ in Cutaneous T Cell Lymphoma

A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 "Do Not Eat" Signal

Phase 1 Study of the Safety and Efficacy of MRG-106, a Synthetic Inhibitor of microRNA-155, in CTCL Patients

PD-L1 Is Regulated By Interferon Gamma and Interleukin 6 through STAT1 and STAT3 Signaling in Cutaneous T-Cell Lymphoma

Preliminary Results of a Phase 1 Trial Evaluating MRG-106, a Synthetic microRNA Antagonist (LNA antimiR) of microRNA-155, in Patients with CTCL

Role of p38γ - NFATc4 - IL17A Pathway As a Potential Therapeutic Target in Cutaneous T Cell Lymphoma

The miRNA Profile of Cutaneous T Cell Lymphoma Correlates with the Dysfunctional Immunophenotype of the Disease

Clinicopathologic Features, Prognosis, and Therapeutic Responses in Patients with Granulomatous Mycosis Fungoides: A Single Center Experience From Memorial Sloan Kettering Cancer Center.

Pralatrexate in Relapsed/Refractory HTLV-1 Associated Adult T-Cell Lymphoma/Leukemia: A New York City Multi-Institutional Experience.

Phase II Multicenter Trial of Lenalidomide: Clinical and Immunomodulatory Effects in Patients with CTCL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only